Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and Drug Administration.It’s a sign that pharmaceutical firm Lilly is making strides to improve the supply issues that have plagued the sector.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making custom-made versions.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications.

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.

Compounded versions of popular weight-loss drugs attracted telehealth companies that marketed services to connect patients with healthcare providers.

Eli Lilly (LLY) weight loss therapy tirzepatide is on track to launch across England’s National Health Service ((NHS)) as part of a phased rollout. Read more here.

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.